@prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix ns2: . @prefix ns1: . @prefix prov: . @prefix ns3: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { ns1:suggest . } sub:provenance { sub:assertion prov:generatedAtTime "2021-12-16T19:49:41.339731"^^xsd:dateTime; prov:wasGeneratedBy "S&T TWOC project version 2" . sub:version prov:value "2"^^xsd:integer . rdf:OBJECT rdfs:label "that AA ( arachidonic acid ) is most suited for such preventive and therapeutic approach" . rdf:OBJECT-POSITION rdfs:label "79"^^xsd:integer . rdf:PREDICATE rdfs:label "suggesting" . rdf:PREDICATE-POSITION rdfs:label "[80]" . rdf:SUBJECT rdfs:label "both prostaglandin E2 ( PGE2 ) and LXA4" . rdf:SUBJECT-POSITION rdfs:label "-2"^^xsd:integer . rdfs:ABSTRACT-UID ns2:50 "8c2l8pfx" . rdfs:SENTENCE rdfs:label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." . rdfs:TRIPLE-UID ns3:8c2l8pfx-TRIPLE-ABSTRACT-PGE211 "8c2l8pfx-TRIPLE-ABSTRACT-PGE211" . rdfs:label "pge2" . rdfs:label "approach" . } sub:pubInfo { sub:assertion prov:wasDerivedFrom . sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB"; npx:hasSignature "J0AyvkWvQqFQquvVzZFP4ZpnEOyvhjDoCS/7wCTqo1evCecaf4+gI+BFMVPH3ac1/yp7jlQfCgPQ2fyGT2qehgTcodVBPBLOpj/c+U6Q5tMBwp65GFmWKCXylr0OjylOTJgnO2GgDDRe7e7wH82DX5u0J0sFoBCThIQbWnsaC3g="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-12-16T19:49:41.339731"^^xsd:dateTime; prov:wasAttributedTo . }